参考文献/References:
[1] DEININGER M,BUCHDUNGER E,DRUKER B J.The development of imatinib as a therapeutic agent for chronic myeloid leukemia[J].Blood,2005,105(7):2640-2653.
[2] 张之南.血液病诊断及疗效标准[M].北京:科学出版社,2007:911-917.
[3] SOKAL J E,COX E B,BACCARANI M,et al.Prognostic discrimination in "good-risk" chronic granulocytic leukemia[J].Blood,1984,63(4):789-799.
相似文献/References:
[1]潘静夫,李素霞,宋传莲,等.小剂量靛玉红为主治疗慢性粒细胞白血病[J].新乡医学院学报,1992,9(02):127.
[2]王慧睿,郭淑利,李 波,等.伊马替尼治疗后慢性粒细胞白血病患者BCR-ABL酪氨酸激酶区突变特征分析[J].新乡医学院学报,2017,34(6):489.[doi:10.7683/xxyxyxb.2017.06.009]
WANG Hui-rui,GUO Shu-li,LI Bo,et al.Characteristics of BCR-ABL tyrosine kinase domain point mutations in imatinib treated chronic myeloid leukemia patients[J].Journal of Xinxiang Medical University,2017,34(6):489.[doi:10.7683/xxyxyxb.2017.06.009]